Natera Inc (NASDAQ:NTRA) CEO Sells $178,918.40 in Stock

Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 7,424 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $24.10, for a total value of $178,918.40. Following the completion of the sale, the chief executive officer now owns 2,268 shares in the company, valued at $54,658.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

  • On Tuesday, March 10th, Steven Leonard Chapman sold 1,147 shares of Natera stock. The shares were sold at an average price of $33.36, for a total value of $38,263.92.
  • On Thursday, January 16th, Steven Leonard Chapman sold 139,340 shares of Natera stock. The shares were sold at an average price of $35.00, for a total value of $4,876,900.00.
  • On Tuesday, January 7th, Steven Leonard Chapman sold 1,849 shares of Natera stock. The shares were sold at an average price of $35.00, for a total value of $64,715.00.
  • On Friday, January 3rd, Steven Leonard Chapman sold 4,739 shares of Natera stock. The shares were sold at an average price of $32.01, for a total value of $151,695.39.

NASDAQ NTRA opened at $25.90 on Friday. The business’s 50-day moving average price is $33.35 and its 200 day moving average price is $35.26. Natera Inc has a twelve month low of $16.87 and a twelve month high of $41.80. The company has a market capitalization of $2.07 billion, a PE ratio of -14.31 and a beta of 1.13. The company has a current ratio of 2.91, a quick ratio of 2.84 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 26th. The medical research company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.16. Natera had a negative return on equity of 120.68% and a negative net margin of 41.30%. The firm had revenue of $83.20 million for the quarter, compared to the consensus estimate of $77.84 million. Equities analysts predict that Natera Inc will post -2.36 EPS for the current year.

Several equities analysts recently weighed in on the company. Craig Hallum reiterated a “buy” rating and set a $49.00 target price on shares of Natera in a research report on Thursday, December 19th. Canaccord Genuity reiterated a “buy” rating and set a $46.00 target price on shares of Natera in a research report on Thursday, March 19th. BidaskClub downgraded Natera from a “buy” rating to a “hold” rating in a research report on Wednesday, March 11th. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a research report on Thursday, January 23rd. Finally, Piper Sandler increased their target price on Natera from $45.00 to $49.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $43.00.

A number of large investors have recently made changes to their positions in NTRA. Marshall Wace LLP acquired a new stake in Natera during the first quarter worth about $264,000. Russell Investments Group Ltd. acquired a new stake in Natera during the third quarter worth about $1,163,000. Tower Research Capital LLC TRC acquired a new stake in Natera during the third quarter worth about $36,000. State Street Corp increased its stake in Natera by 4.8% during the third quarter. State Street Corp now owns 2,065,518 shares of the medical research company’s stock worth $67,749,000 after acquiring an additional 95,038 shares during the last quarter. Finally, HWG Holdings LP increased its stake in Natera by 10,712.3% during the third quarter. HWG Holdings LP now owns 28,112 shares of the medical research company’s stock worth $922,000 after acquiring an additional 27,852 shares during the last quarter. Institutional investors own 91.88% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: What are benefits of a growth and income fund?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.